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Cell surface expressionThe melanocortin-3 receptor (MC3R) is a member of family A rhodopsin-like G protein-coupled receptors.
Mouse genetic studies suggested that MC3R and the related MC4R are non-redundant regulators of energy
homeostasis. Lack of Mc3r leads to higher feed efﬁciency and fat mass. However, until now only a few
MC3R mutations have been identiﬁed in humans and the role of MC3R in the pathogenesis of obesity was
unclear. In the present study, we performed detailed functional studies on nine naturally occurring MC3R
mutations recently reported. We found that all nine mutants had decreased cell surface expression. A260V,
M275T, and L297V had decreased total expression whereas the other six mutants had normal total expres-
sion. Mutants S69C and T280S exhibited signiﬁcant defects in ligand binding and signaling. The dramatic
defects of T280S might be partially caused by decreased cell surface expression. In addition, we found
mutants M134I and M275T had decreased maximal binding but displayed similar signaling properties as
wild-type MC3R. All the other mutants had normal binding and signaling activities. Co-expression studies
showed that all mutants except L297V did not affect wild-type MC3R signaling. Multiple mutations at T280
demonstrated the necessity of Thr for cell surface expression, ligand binding, and signaling. In summary,
we provided detailed data of these novel human MC3R mutations leading to a better understanding of
structure–function relationship of MC3R and the role of MC3R mutation in obesity.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Obesity, due to imbalance of energy intake and energy expenditure,
has become an alarming epidemic in the western world. The causes of
obesity include environmental, psychosocial and genetics factors [1].
Through the studies of identifying genetic factors of obesity, mutations
in several genes encoding proteins involved in regulation of energy
homeostasis have been found to be associated with obesity [2–5].
Themelanocortin-3 receptor (MC3R) is considered a potential regula-
tor of energy homeostasis [6–8]. It is a member of family A G protein-
coupled receptors (GPCRs) [9,10]. The principal endogenous ligands of
MC3R are the small peptides cleaved from the proopiomelanocortin
(POMC), including α- and γ-melanocyte-stimulating hormones (MSH).
The endogenous antagonist for MC3R is Agouti-related protein [11,12],
which we showed to be also an inverse agonist for the MC3R [13].
MC3R is expressed in brain, placenta, stomach, duodenum, pancreas [9],MC3R, human melanocortin-3
nocyte stimulating hormone;
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l rights reserved.kidney [14], as well as macrophages [15]. The highest density of MC3R
mRNA has been found in hypothalamus, especially the ventromedial
hypothalamic nucleus, the arcuate nucleus and the posterior hypotha-
lamic area [16]. Since hypothalamus plays a key role in controlling
energy homeostasis [11,17], it was hypothesized that MC3R is involved
in the regulation of energy homeostasis.
Rodent genetic studies showed that in the absence of Mc3r, mice
did not exhibit hyperphagia [6,7]. Due to a higher feed efﬁciency
and alterations in nutrient partitioning, Mc3r knockout mice have
increased fat mass, reduced lean mass, and normal metabolism with
normal or even slightly decreased food intake [6–8]. In situ hybridiza-
tion indicated that MC3R mRNA is distributed similarly with that of
POMC mRNA in the arcuate nucleus, suggesting that MC3R also
served as an inhibitory autoreceptor on POMC neurons and therefore
stimulate food intake [18]. Recently, it is also reported that MC3R
plays a critical role in entrainment to restricted feeding [19,20].
The role of MC3R mutation in human obesity is controversial.
Unlike MC4R, where over 150 mutations have been identiﬁed [21],
relatively few MC3R mutations have been reported [22–28] (reviewed
in [29]). Recently, nine novel naturally occurring MC3R mutations
were reported in Singaporean patients, two North American cohorts,
and a Finnish cohort [24,26,30] (Fig. 1), but the functions of thesemuta-
tions were incompletely characterized. In this study, we performed
detailed functional analysis of these mutations in vitro.
F
E
V
K
I
E
F
LS
P
LG
V
Q
S
L
I
L
V I
L
A V
V
R
N G N L H S
P
M
YF
F
S LA
V
A
M
L
S
L
N
A
S V
E
TI
M
IA
V
H
Q
M
D
F
I
N
I I
D
S
M C
A
V
N
C
A
IA
V D
Y V
T
I
F
Y
A
R
K
A
T
LI
V A
I
VC
GC
C GV
V
V
I
V
T
R
SY
R I A P A
Y
V
F
L
E S K
M
V
M
I
V
F
C
A
M
I
L
T
M
L
L
G
H
M
FL
F
H
L
V K
G
A
P
H
M
KG
VT
P
I
L
I
F
W
A
F
LH
L
LI
I
T
T C I C
T
A
HF
TY
N
V
I
L
C M
F
C
S
T
Y
D
E
L
S
L
R
N
T
R
E I C C
N
G
M
N
L
H
S
D
Y L T F
F
I
L R H S I M
T
V
C
F
A
S
C-terminal
V
M
F
Y
C
Y
A
N
P
L
I
R
L
F T P S S NGA PHSS F C AE MS PV
G
D
V
L
A
I
F
N
FI
V
A
L
S
Q N P L N L Q L
P
C
S
Y
P
Q
L
V
E
N
V
D
L
E
Q
L
I
L
L
R
I
X
M
C
C
S W
A
P
F
I
L
G
S
D
L
Q G
F T L
PAL
SFQ LI SGS DK Y
SL
S
T
S
Q
E
L E V V F R
L
L
P
GA
T
V
-3xHA- 
S69C 
A70T
I87T 
M134I 
L249V
A260V 
M275T 
T280S
L297V
Q
Fig. 1. Schematic model of the human MC3R with the mutations studied in this study is highlighted.
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2.1. Plasmid and peptides
Wild-type (WT) human MC3R (hMC3R) cDNA tagged with 3×HA
tags at the N-terminus inserted in vector pcDNA3.1 was obtained
from Missouri S&T cDNA Resource Center (http://www.cDNA.org/,
Rolla, MO). [Nle4, D-Phe7]-α-MSH (NDP-MSH) was purchased from
Bachem (King of Prussia, PA). α-MSH was purchased from Phoenix
Pharmaceuticals (Belmont, CA). D-Trp8-γ-MSH was obtained from
Peptides International (Louisville, KY). 125I-NDP-MSH was obtained
from the Peptide Radioiodination Service Center at the University of
Mississippi (University, MS).2.2. Site-directed mutagenesis of the human MC3R
Human MC3R mutations were generated by QuikChange™ site-
directed mutagenesis kit (Stratagene, La Jolla, CA). Plasmids were pre-
pared using IsoPure DNA puriﬁcation kits from Denville Scientiﬁc
(Metuchen, NJ). Automated DNA sequencing was performed by the
DNA Sequencing Facility of University of Chicago Cancer Research
Center (Chicago, IL) to conﬁrm that the correctmutationwas generated
and no errors were introduced during the cycling reactions.2.3. Cells and transfections
Human Embryonic Kidney (HEK) 293T cells, obtained fromAmerican
Type Culture Collection (Manassas, VA), were grown at 5% CO2 in
Dulbecco's Modiﬁed Eagle's Medium (DMEM) supplemented with
50 μg/ml of gentamicin, 100 IU/ml of penicillin, 100 μg/ml of streptomy-
cin, 20 μg/ml of amphotericin B, 10 mM Hepes and 10% newborn calf
serum. Cells were plated on gelatin-coated 35 mm 6-well clusters from
Corning (Corning, NY). When the cells reached 50–70% conﬂuency,
transient transfection was performed with the calcium phosphate pre-
cipitation method [31]. One microgram of plasmid in 2 ml media was
used per 35 mm well. Cells were incubated for approximately 48 hafter transfection before used tomeasure ligand binding and ligand stim-
ulated cAMP generation.
2.4. Ligand binding to intact cells
Forty-eight hours after transfection, cells were washed twice with
warm Waymouth's MB752/1 media (Sigma-Aldrich, St. Louis, MO)
containing 1 mg/ml bovine serum albumin (BSA) (referred to as
Waymouth/BSA). Fresh Waymouth/BSA was added to each well, incu-
batedwith 50 μl of 125I-NDP-MSH (~100,000 cpm)with orwithout dif-
ferent concentrations of unlabeled NDP-MSH,α-MSH or D-Trp8-γ-MSH
at 37 °C for 1 h. The total volume in each well was 1 ml. The ﬁnal con-
centrations of unlabeled ligands are indicated in the ﬁgures. After incu-
bation, cells were washed twice with cold Hank's balanced salt solution
(Sigma-Aldrich) containing 1 mg/ml BSA to terminate the reaction.
Then cells of each well were solubilized with 100 μl of 0.5 N NaOH.
Cell lysates were collected with cotton swabs and counted in a
gamma counter. All determinations were performed in duplicate and
the experiment was performed at least three times. Maximal binding
capacity (Bmax) and IC50 values were calculated using GraphPad
Prism 4.0 (San Diego, CA).
2.5. Ligand stimulated cAMP generation
After 48 h incubation, transfectedHEK-293T cellswerewashed twice
with warm Waymouth/BSA. Then fresh Waymouth/BSA containing
0.5 mM isobutylmethylxanthine (Sigma-Aldrich) was added to each
well. After 15 min incubation at 37 °C, either Waymouth/BSA alone or
different concentrations of ligands were added. The total volume in
each well was 1 ml. The ﬁnal concentrations of the ligands are indicated
in the ﬁgures. After 1 h incubation at 37 °C, cells were then placed on
ice to terminate the reaction, media were aspirated and intracellular
cAMP were extracted with 0.5 N percholoric acid containing 180 μg/ml
theophylline. The cAMP concentrations were measured by radioimmu-
noassay [13,32]. All determinations were performed in triplicate and
the experiment was performed at least three times. Maximal responses
(Rmax) and EC50 values were calculated by GraphPad Prism 4.0.
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HEK293 cells stably transfected with WT or mutant hMC3Rs
containing 3×HA tags at the N-terminus were plated onto poly-D-
lysine-coated slides (Biocoat cellware from Falcon) and were immu-
nostained with Alexa Flour 488-conjugated anti-HA.11 antibody on
the third day using a protocol based on our previous report [33].
Brieﬂy, on the day of experiment, cells were washed with ﬁltered
phosphate buffered saline for immunohistochemistry (PBS-IH) for
three times and then were ﬁxed with 4% paraformaldehyde in
PBS-IH for 30 min. After three more washes with PBS-IH, cells were
incubated with blocking solution (5% BSA in PBS-IH) for 1 h at room
temperature, and incubated with Alexa Fluor 488-labeled anti-
HA.11 antibody (Covance, Berkeley, CA) diluted 1:100 in PBS-IH
containing 0.5% BSA for 1 h at room temperature in the dark. Then
the cells were washed ﬁve times with PBS-IH and covered with
VectaShield Mounting Media (Vector Laboratories) and a glass cover-
slip. Images were collected with a Bio-Rad laser scanning confocal
microscope with excitation by 488 nm argon laser and detected
with a 530- to 560-nm ﬁlter.2.7. Quantiﬁcation of MC3R expression by ﬂow cytometry
Flow cytometry was performed as described previously [34–36].
Brieﬂy, HEK293 cells were plated on gelatin-coated 35 mm 6-well
clusters and transfected with 4 μg of plasmid in 2 ml media for each
well. After 48 h incubation, cells were washed once with ﬁltered
PBS-IH, detached, and then precipitated by centrifugation at 500×g.Fig. 2. Signaling and ligand binding properties of the WT and mutant hMC3Rs with NDP-MS
constructs and binding and signaling of the hMC3Rs were measured as described in Materia
constructs were stimulated with different concentrations of NDP-MSH. Intracellular cAMP
determinations within one experiment. In (B), different concentrations of unlabeled NDP-MS
shown are expressed as % of WT binding±range from duplicate determinations within oneCells were ﬁxed by 4% paraformaldehyde in PBS-IH for 30 min, and
for measuring total expression, cells were permeabilized with 1%
Triton X-100 in PBS-IH for 4 min (this step was omitted for measuring
cell surface expression). Cells were then blocked with PBS-IH
containing 5% BSA for 1 h. The cells were then stained with primary
anti-HA.11 antibody (Covance) diluted 1:50 in PBS-IH containing 0.5%
BSA for 1 h, and washed with PBS-IH containing 0.5% BSA. The second-
ary Alexa Fluor 488-conjugated goat anti-mouse IgG (Invitrogen,
Carlsbad, CA) diluted 1:2000 in PBS-IH containing 0.5% BSA was
added under low light. After 1 h incubation, cells were washed and
resuspended in PBS-IH with 0.5% BSA. An Accuri ﬂow cytometer with
a 488-nmwavelength laser was applied to quantify hMC3Rmutant ex-
pression in 15,000 cells from each transfection. Cells transfected with
pcDNA3.1 empty vector were used as control for background staining.
All the incubations and washes were performed at room temperature.
The expression levels of the mutants were calculated as percentage
of WT hMC3R expression as described before using the formula:
[mutant−pcDNA3]/[WT−pcDNA3]×100% [34–36]. Samples of cells
transfected with pcDNA3.1 empty vector or WT hMC3R were included
in each experiment and processed togetherwith the samples transfected
with mutant hMC3Rs.2.8. Statistical analyses
Student's t test was used to determine the signiﬁcance of differ-
ences in the expression, ligand binding and signaling parameters
between WT and mutant hMC3Rs. Statistical analysis was carried
out using GraphPad Prism 4.0.H as the ligand. HEK293T cells were transiently transfected with the indicated hMC3R
ls and methods. In (A), HEK293T cells transiently transfected with the indicated hMC3R
levels were measured using RIA. Results are expressed as the mean±SEM of triplicate
H were used to displace the binding of 125I-NDP-MSH to hMC3Rs on intact cells. Results
experiment. All experiments were performed at least three times.
Table 1
Binding and signaling properties of WT and mutant hMC3Rs with NDP-MSH as the
ligand.
hMC3R n NDP-MSH binding NDP-MSH-stimulated cAMP
IC50 (nM) EC50 (nM) Rmax (% WT)
WT 8 2.06±0.37 0.36±0.02 100.00
S69C 3 0.81±0.04b 0.39±0.07 54.67±8.49a
A70T 3 1.88±0.56 0.37±0.13 103.96±2.18
I87T 3 1.08±0.11a 0.29±0.09 91.05±10.14
M134I 3 1.94±0.49 0.51±0.08 80.31±12.26
L249V 3 1.98±0.41 0.43±0.12 84.98±18.29
A260V 3 1.53±0.03 0.52±0.17 91.96±18.09
M275T 3 2.22±0.65 0.46±0.04 89.72±7.27
T280S 3 1.07±0.13a 0.29±0.15 12.86±5.64b
L297V 3 2.30±0.66 0.49±0.23 106.87±14.46
The data are expressed as the mean±SEM for the mutant hMC3Rs. The maximal
responses (Rmax) were 2142±507.5 pmol cAMP/106 cells for WT hMC3R.
a Signiﬁcantly different from the WT hMC3R, pb0.05.
b Signiﬁcantly different from the WT hMC3R, pb0.01.
Table 2
Binding and signaling properties of WT and mutant hMC3Rs with D-Trp8-γ-MSH as the
ligand.
hMC3R n D-Trp8-γ-MSH binding D-Trp8-γ-MSH-stimulated cAMP
IC50 (nM) EC50 (nM) Rmax (% WT)
WT 15 9.86±2.47 0.76±0.08 100.00
S69C 3 8.20±2.38 0.57±0.11 42.59±1.40a
A70T 3 4.38±1.27 0.95±0.24 145.97±40.50
I87T 3 4.49±1.52 0.38±0.10b 82.38±13.93
M134I 3 18.98±1.26 1.26±0.13 128.96±31.04
L249V 3 6.19±1.25 0.52±0.07 111.78±7.54
A260V 3 4.99±1.49 1.01±0.17 99.85±33.38
M275T 3 4.49±0.21 0.45±0.04 119.87±29.30
T280S 3 0.52±0.05c 2.17±0.48 3.76±1.00b
L297V 3 4.53±1.51 0.46±0.02 137.78±19.95
The data are expressed as the mean±SEM for the mutant hMC3Rs. The maximal
responses (Rmax) were 1747.31±433.39 pmol cAMP/106 cells for WT hMC3R.
a Signiﬁcantly different from the WT hMC3R, pb0.001.
b Signiﬁcantly different from the WT hMC3R, pb0.01.
c Signiﬁcantly different from the WT hMC3R, pb0.05.
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3.1. Signaling properties of the mutant hMC3Rs in response to NDP-MSH,
D-Trp8-γ-MSH or α-MSH stimulation
In order to investigate whether the missense mutations in human
MC3R cause any alterations in the function of the receptor, the levels
of intracellular cAMP generated in response to the agonists were
measured.
We ﬁrst studied the signaling response to NDP-MSH stimulation.
NDP-MSH is a superpotent analog of MCRs except MC2R [37]. As
expected, NDP-MSH caused dose-dependent increases in intracellular
cAMP levels in cells transfected with WT hMC3R. Fig. 2A showed
the results of a typical experiment. In response to NDP-MSH, all
the mutants showed similar EC50 as that of WT hMC3R. S69C and
T280S displayed signiﬁcant reduction in the maximal levels of cAMPFig. 3. Signaling and ligand binding properties of the WT and mutant hMC3Rs with D-Trp
D-Trp8-γ-MSH was used as the ligand instead of NDP-MSH.generation compared to that of WT hMC3R (Table 1). The other mu-
tants had apparent normal signaling.
Then the signaling property was tested with D-Trp8-γ-MSH
(Fig. 3A), which is a superpotent and more selective analog of γ-MSH
[38]. γ-MSH is a potent endogenous MC3R agonist. With the stimula-
tion of D-Trp8-γ-MSH, similar results to NDP-MSH stimulation were
obtained (Table 2). Only S69C and T280S had signiﬁcant decreases in
maximal signaling compared to WT hMC3R (Table 2).
The signaling property was also investigated with the stimulation
of α-MSH, an endogenous agonist (Fig. 4A). The EC50 of WT hMC3R
for α-MSH was about 5-fold higher than that for NDP-MSH. S69C
and T280S displayed signiﬁcantly increased EC50 and signiﬁcantly
decreased maximal signaling (Table 3). All the other mutants had
normal signaling properties compared to WT hMC3R.8-γ-MSH as the ligand. See the legend to Fig. 2 for details. The only difference is that
Fig. 4. Signaling and ligand binding properties of the WT and mutant hMC3Rs with α-MSH as the ligand. See the legend to Fig. 2 for details. The only difference is that α-MSH was
used as the ligand instead of NDP-MSH.
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ity that can easily be measured, the WT hMC3R has little constitutive
activity [39]. The basal cAMP levels in cells transfected with WT
hMC3R were similar to the basal cAMP levels in cells transfected
with empty vector pcDNA3 [39]. In the current study, none of the
mutants had increased basal activity compared to WT hMC3R (Fig. 5).
S69C and T280S had small but statistically signiﬁcant decreases in
basal activities (Fig. 5).3.2. Ligand binding of the mutant hMC3Rs
To investigate whether the mutants had normal binding activity,
competitive ligand binding assays were performed. The three ligandsTable 3
Binding and signaling properties of WT and mutant hMC3Rs with α-MSH as the ligand.
hMC3R n α-MSH binding α-MSH-stimulated cAMP
IC50 (nM) EC50 (nM) Rmax (% WT)
WT 13 36.68±6.50 1.68±0.19 100.00
S69C 4 6.75±1.57a 4.42±0.59a 36.34±0.89b
A70T 3 30.39±9.27 2.42±0.09 194.46±79.36
I87T 3 6.60±1.75a 1.96±0.52 107.42±22.47
M134I 3 31.1±13.28 7.48±2.05 129.69±39.45
L249V 3 27.73±1.81 3.69±0.94 133.33±28.31
A260V 3 26.00±3.69 2.07±0.51 97.42±21.32
M275T 3 24.76±8.99 3.64±0.87 71.97±18.10
T280S 3 3.44±0.60a 22.39±5.72a 4.20±3.32c
L297V 3 32.31±10.73 2.37±0.37 145.61±31.40
The data are expressed as the mean±SEM for the mutant hMC3Rs. The maximal
responses (Rmax) were 1407.77±411.25 pmol cAMP/106 cells for WT hMC3R.
a Signiﬁcantly different from the WT hMC3R, pb0.05.
b Signiﬁcantly different from the WT hMC3R, pb0.001.
c Signiﬁcantly different from the WT hMC3R, pb0.01.used above were used as the competitors. When NDP-MSH was used
as ligand (Fig. 2B), S69C and T280S showed signiﬁcantly decreased
IC50s (Table 1). All the other mutants had similar IC50s as the WT
hMC3R. When D-Trp8-γ-MSH was used as the competitor (Fig. 3B),
only T280S showed signiﬁcantly reduced IC50 (Table 2) whereas the
other mutants had similar IC50s as the WT hMC3R. When α-MSH
was used as the competitor (Fig. 4B), three mutants (S69C, I87T and
T280S) had signiﬁcantly decreased IC50s whereas the other mutants
had similar IC50s as the WT hMC3R (Table 3).
As shown in Fig. 6, four mutants (S69C, M134I, M275T and T280S)
showed signiﬁcantly reduced maximal binding. All the other mutants
had relatively normal maximal binding.Fig. 5. Basal activities of the WT and mutant hMC3Rs. The results are expressed as % of
WT basal signaling. Shown are mean±SEM of 5–8 experiments. The basal cAMP levels
in HEK293T cells expressing WT hMC3R were 9.68±1.47 pmol/106 cells (mean±
SEM). Star (*) indicates signiﬁcantly different from WT hMC3R.
Fig. 6.Maximal binding of the WT and mutant hMC3Rs. The results are expressed as %
of WTmaximal binding. Shown are mean±SEM of all the binding experiments. Star (*)
indicates signiﬁcantly different from WT hMC3R.
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To investigate the localization of these mutants, especially the
mutants that displayed functional defects, confocal microscopy was
performed. The Alexa-Fluor labeled HA antibody, which selectively
binds to the three-tandem HA epitope tags at the N-terminus of
hMC3R, revealed the localization of hMC3R. As shown in Fig. 7,
every mutant was expressed at the cell surface, including the mutants
that had signiﬁcant defects in ligand binding and signaling properties,
such as S69C and T280S.T280S
WT S69C
M134I
L297V
L249V
Fig. 7. Confocal imaging of cell surface expression of WT and mutant hMC3Rs. The WT
Flour-conjugated anti-HA monoclonal antibody and imaged by confocal microscopy. This e3.4. Quantiﬁcation of mutant hMC3R expression by ﬂow cytometry
To quantitate mutant hMC3R expression, ﬂow cytometry was
performed. The data in non-permeabilized cells showed that all nine
mutants had signiﬁcantly decreased cell surface expression compared
to WT hMC3R (Fig. 8A). As shown in Fig. 8B, the results in perme-
abilized cells showed that A260V, M275T, and L297V had small but
statistically signiﬁcant decreases in total expression levels. The
other six mutants had similar total expression levels as that of WT
hMC3R.
3.5. Co-expression studies of hMC3R mutations
To investigate whether the mutant hMC3Rs had any dominant
negative activity on WT hMC3R signaling, co-expression experiments
were performed. WT and empty vector or mutant hMC3Rs were
co-transfected into HEK293T cells with the ratio of 1:1. As shown in
Fig. 9, L297V exhibited slight inhibition on WT hMC3R signaling. All
the other mutants had no dominant negative activity on WT hMC3R
signaling (Fig. 9 and Table 4).
3.6. Multiple mutagenesis of T280
Although retaining some binding activity, T280S was almost
devoid of signaling, which attracted our attention. The only difference
between threonine and serine is that threonine has an extra methyl
group. To further investigate the importance of T280 in hMC3R,
multiple mutations were generated, changing T280 to hydrophobic
(Ala, Leu and Tyr), polar (Cys), negatively charged (Asp), or positively
charged (Arg) residues. The ligand binding and signaling properties ofA70T 
A260V
I87T
M275T
or mutant 3HA-MC3Rs stably expressed in HEK293 cells were stained with Alexa
xperiment was done twice with similar results.
Fig. 8. Quantitative measurement of cell surface (A) or total (B) expression of WT and
mutant hMC3Rs by ﬂow cytometry. In (A), cell surface expression of the WT and
mutant hMC3Rs were measured by ﬂow cytometry. The results were expressed as %
of WT cell surface expression levels after correction of the nonspeciﬁc staining in
cells transiently transfected with the empty vector as described in Materials and
methods. Data were mean±SEM of 8–9 experiments. Star (*) indicates signiﬁcantly
different from WT hMC3R. In (B), total expression of the WT and mutant hMC3R
were measured by ﬂow cytometry. The results were expressed as % of WT total expres-
sion levels after correction of the nonspeciﬁc staining in cells transiently transfected
with the empty vector as described in Materials and methods. Data were mean±
SEM of 6–7 experiments. Star (*) indicates signiﬁcantly different from WT hMC3R.
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and Table 5). The results showed that no ligand binding could be
detected for T280A, T280C, T280R and T280Y. The maximal binding
for T280L was signiﬁcantly decreased, whereas T280D had similar
maximal binding as the WT hMC3R. T280D and T280L had similar IC50
to that of WT hMC3R. Signaling experiments showed that T280A,
T280C, T280D, T280R, and T280Y had no response to NDP-MSH stimu-
lation. T280L had similar EC50 asWT hMC3R, but themaximal signaling
was signiﬁcantly decreased (Fig. 10 and Table 5).
The results of ﬂow cytometry showed that in non-permeabilized
cells, all mutants were expressed at the cell surface, but at signiﬁcantly
lower levels compared to the WT hMC3R (Fig. 8A). In permeabilized
cells, all mutants had similar total expression levels as the WT hMC3R
(Fig. 8B).4. Discussion
In this study, we performed detailed functional analysis of nine
naturally occurring MC3R mutations that have not been studied in
detail before. Among these nine mutations, S69C was identiﬁed in a
lean person, and the other mutations were found in obese patients
[24,26,30]. All mutants had decreased cell surface expression. Six
mutants had normal total protein expression. A260V, M275T, and
L297V had small, although statistically signiﬁcant, decreases in total
protein expression. Four mutants (S69C, M134I, M275T and T280S)had signiﬁcantly decreased maximal binding and two mutants
(S69C and T280S) had signiﬁcant defects in signaling.
To investigate whether the mutant hMC3Rs were mislocalized, we
performed confocal microscopy and ﬂow cytometry. Confocal micros-
copy in non-permeabilized cells showed that all mutants were
expressed on the cell surface (Fig. 7) but ﬂow cytometry showed
that cell surface expression levels were signiﬁcantly decreased to
about 50–75% of WT hMC3R (Fig. 8A). Flow cytometry in perme-
abilized cells showed that six mutants had normal total protein
expression levels whereas A260V, M275T, and L297V had small,
although statistically signiﬁcant, decreases in total protein expression
levels (Fig. 8B). These results suggest that six mutants, including
S69C, A70T, I87T, M134I, L249V, and T280S, were retained intracellu-
larly due to misfolding. The majority of GPCR mutations causing
human diseases belong to this class [40] and intracellular retention
comprises the majority of MC4R mutations causing obesity [41].
A260V, M275T, and L297V had small decreases in total protein
expression levels (Fig. 8B). Premature termination and frameshift
mutations are predicted to cause decreased protein levels, partly
due to nonsense-mediated mRNA decay [40]. However, only a few
examples were reported for missense mutations that result in de-
creased total protein expression. A naturally occurring synonymous
mutation of human dopamine D2 receptor was reported to markedly
change mRNA stability through changing mRNA secondary structure
and therefore caused decreased protein expression [42]. Whether
similar mechanism accounts for the decreased total expression for
the three hMC3Rmutations in the present study remains to be studied.
We reported recently that severalmissensemutations in theMC4R gene
also cause decreased total expression levels [35,36]. It should be empha-
sized that total expression levels were not measured in many of the
functional studies on naturally occurring mutations in GPCRs that
cause human diseases.
Mutant T280S exhibited dramatic functional defects in both bind-
ing and ligand-stimulated intracellular cAMP generation (Figs. 2–6
and Tables 1–3). T280S also had signiﬁcantly reduced cell surface
expression (Figs. 7 and 8). The functional defects of T280S might
be due to, at least partially, the decrease in cell surface expression.
Comparing binding and signaling data suggested that it was also de-
fective in signaling per se. T2806.36 sits deeply in the transmembrane
domain 6 (TM6), near the intracellular surface (6.36 is a nomencla-
ture system illustrating the position of a residue in TM, [43]). TM6
plays an important role in GPCR signaling mechanism [44]. Therefore,
we generated additional mutations at codon 280 changing Thr to
different classes of amino acids and performed detailed functional
analysis (Fig. 10). The results showed that all these mutants were
expressed at the cell surface but had signiﬁcantly decreased cell sur-
face expression levels (Fig. 8A), although the total expression levels
were normal (Fig. 8B). No binding or signaling could be detected for
T280A, T280C, T280R and T280Y. Therefore these mutants were
defective in ligand binding. T280D was a signaling defective mutant
with normal ligand binding. T280L displayed similar EC50 and IC50
as WT hMC3R, but had signiﬁcantly decreased maximal binding and
signaling (Fig. 10 and Table 5). We suggested that for T280L, due to
decreased cell surface expression, maximal binding and signaling
were decreased. Our data demonstrated the importance of T280 in
different aspects of hMC3R functions including receptor expression,
ligand binding and signaling. Changing Thr to Ser that has similar
structure as Thr caused signiﬁcant functional defects; however,
mutating the polar Thr to the negatively charged Asp or hydrophobic
nonpolar Leu maintained partial receptor function. These results
demonstrated that it is not reliable to predict the functional ramiﬁca-
tion of mutations simply based on their amino acid characteristics.
Instead detailed functional studies are necessary.
Mutants M134I andM275T had decreased maximal ligand binding
(Fig. 6), consistent with their reduced cell surface expression. But
they had normal signaling (Tables 1–3), suggesting the presence of
Fig. 9. Accumulation of intracellular cAMP in cells expressing WT and/or mutant hMC3Rs. HEK293T cells were transiently transfected with the indicated MC3R constructs, and
intracellular cAMP levels were measured by RIA. The same amount of WT hMC3R plasmid was present in all groups. Empty vector was added to keep plasmid concentrations con-
stant among the different groups. Results are expressed as the mean±SEM of triplicate determinations within one experiment. All experiments were performed at least three
times.
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Asian children and their obese mothers. Both mother and child carry-
ing M134I had type 2 diabetes [24] indicating that decreased cell sur-
face expression might cause decreased signaling in vivo.
Previously, functional studies were reported for several naturally
occurring MC3R mutations. For I183N, ﬁrst reported in 2002 [22],
three studies showed that the mutation causes a total loss of signaling
[24,45,46]. Three mutations, A293T, I335S, and X361S, were identiﬁed
from an Italian cohort [25]. Two groups independently showed that
I335S is a loss of function mutation, whereas no signiﬁcant defect
could be identiﬁed for A293T and X361S [25,39]. Recent genetic stud-
ies in Europe reported newMC3Rmutations in obese patients causing
dramatic functional defects [27,28]. Of the three mutations identiﬁed
from an obese cohort in Belgium (N128S, V211I, and L299V), func-
tional studies showed that L299V has impaired function due to
decreased cell surface expression resulting in defective signaling,Table 4
NDP-MSH-stimulated signaling in cells co-transfected with WT and/or mutant
hMC3Rs.
hMC3R n NDP-MSH-stimulated cAMP
EC50 (nM) Rmax (% WT)
WT+pcDNA 5 1.67±0.41 100.00
WT+S69C 3 1.66±0.71 94.05±6.76
WT+A70T 3 3.13±1.96 121.06±34.59
WT+I87T 3 1.41±0.47 95.62±13.69
WT+M134I 3 0.55±0.14 80.74±6.23
WT+L249V 3 1.04±0.18 86.39±8.48
WT+A260V 3 1.42±0.31 85.63±9.52
WT+M275T 3 0.48±0.09 92.66±17.08
WT+T280S 4 1. 50±0.23 81.20±22.68
WT+L297V 3 0.90±0.35 78.89±2.32a
The data are expressed as the mean±SEM for the mutant hMC3Rs. The maximal
responses (Rmax) were 2452.40±308.11 pmol cAMP/106 cells for WT hMC3R+pcDNA.
a Signiﬁcantly different fromWT hMC3R+pcDNA, pb0.05.whereas although N128S and V211I are expressed on the cell surface,
N128S has increased EC50 and V211I has decreased maximal response
in response to α-MSH stimulation [28]. Another study showed that
the prevalence of functionally relevant mutations is signiﬁcantly
higher in the obese group in Italian and French cohorts [27].
Because the mutations were identiﬁed in heterozygous state, we
performed co-transfection experiments to investigate whether the
mutant receptor had dominant negative effect on the WT receptor
signaling. Our data showed that most of the mutants have no domi-
nant negative effect (Fig. 9 and Table 4). Only L297V had small,
although signiﬁcant, effect on WT hMC3R signaling (Fig. 9 and
Table 4). These data were consistent with previous studies demon-
strating lack of dominant negative effect on the other MC3R muta-
tions [39,45], similar to the MC4R mutations [47,48]. It has been
reported that MC3R homodimerize [49] and dimerization is consid-
ered to be responsible for dominant negative activity exerted by
some mutant GPCRs [50] including MC4R [49,51]. Whether the
mutant receptors studied herein can heterodimerize with the WT
receptor remains to be investigated.
In the related MC4R, more than 150 distinct mutations have been
reported and mutations in the MC4R are widely accepted to be the
most common monogenic form of obesity and an important contrib-
utor to polygenic obesity (reviewed in [21]). Genetic, clinical, and
pharmacological data from numerous studies were supportive of
this hypothesis. However, relatively few mutations in the MC3R
have been identiﬁed in humans and their relevance in obesity patho-
genesis is still hotly debated (reviewed in [29]). At least twenty-four
mutations in the MC3R have been identiﬁed in humans. In a recent
editorial, we suggested that because of the phenotype ofMc3r knock-
out mice (increased fat mass with normal body weight), human
genetic studies on the MC3R mutation and disorders in energy bal-
ance should pay special attention to the body fat (adiposity) instead
of simple body weight (for example, using body mass index) [29],
the so-called “deep phenotyping” [52]. Large-scale molecular genetic
Fig. 10. Multiple mutagenesis of T280. T280 was mutated to Ala, Cys, Leu, Asp, Arg, and Tyr. The signaling (A) and ligand binding (B) properties of these mutants were measured
using NDP-MSH as the ligand.
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groups), with thorough phenotyping, combined with detailed func-
tional studies as presented in this manuscript, will likely help to clar-
ify the potential pathogenic role of MC3R mutation in human energy
balance disorder [29].
In summary, we obtained detailed functional data of nine natural-
ly occurring MC3R mutations. We demonstrated that T280S might be
a possible pathogenic cause for human obesity and T280 played an
important role in MC3R expression, binding and signaling, contribut-
ing to a better understanding of structure–function relationship of
MC3R. Whether and how the mutants that did not affect signaling
are related to human adiposity remains to be further studied, prefer-
ably vetted in vivo. Their decreased cell surface expression likely will
have physiological consequence. The accumulating literature supports
the hypothesis thatMC3Rmutations are associated with human obesity
or adiposity, predisposing the carrier to obesity in the current obesogenic
environment. This predisposition ismost likely due to haploinsufﬁciency
rather than dominant negative activity.
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IC50 (nM) Bmax (% WT) EC50 (nM) Rmax (% WT)
WT 3 4.56±2.24 100.00 3 0.63±0.41 100.00
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T280D 3 3.91±1.68 115.97±10.06 3 ND ND
T280L 3 4.06±2.26 37.78±8.48a 3 1.47±1.18 26.35±3.15b
T280R 3 ND ND 3 ND ND
T280Y 3 ND ND 3 ND ND
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The data are expressed as the mean±SEM for the mutant hMC3Rs. The maximal
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